Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PRR013
MIFTS: 40

Prurigo Nodularis

Categories: Rare diseases, Skin diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Prurigo Nodularis

About this section

MalaCards integrated aliases for Prurigo Nodularis:

Name: Prurigo Nodularis 54 56 74
Nodular Prurigo 54

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Skin diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

ICD10 34 L28.1
UMLS 74 C0263353
Sources

Summaries for Prurigo Nodularis

About this section
NIH Rare Diseases : 54 Prurigo nodularis (PN) is a skin disease that causes hard, itchy lumps (nodules) to form on the skin. The itching (pruritus) can be intense, causing people to scratch themselves to the point of bleeding or pain. Scratching can cause more skin lesions to appear. The itching is worsened by heat, sweating, or irritation from clothing. In some cases, people with PN have a history of other diseases including eczema (atopic dermatitis), lymphoma, HIV infection, severe anemia, or kidney disease.  The exact cause of PN is unknown. Although scratching is known to cause more nodules to appear, it is unclear what causes the itching to develop in the first place. Diagnosis of the disease is based on observing signs such as extremely itchy skin with the formation of nodules. In some cases, a skin biopsy is used to confirm the diagnosis. Treatment may include corticosteroid creams, oral medications, cryotherapy, or photochemotherapy.

MalaCards based summary : Prurigo Nodularis, also known as nodular prurigo, is related to anhidrosis and peripheral nervous system disease. An important gene associated with Prurigo Nodularis is RNASE3 (Ribonuclease A Family Member 3), and among its related pathways/superpathways are Phospholipase-C Pathway and p70S6K Signaling. The drugs Lidocaine and Peripheral Nervous System Agents have been mentioned in the context of this disorder. Affiliated tissues include skin, kidney and thyroid.

Wikipedia : 77 Prurigo nodularis (PN), also known as nodular prurigo, is a skin disease characterised by pruritic... more...

Sources

Related Diseases for Prurigo Nodularis

About this section

Diseases related to Prurigo Nodularis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 94)
# Related Disease Score Top Affiliating Genes
1 anhidrosis 30.1 NGF NGFR
2 peripheral nervous system disease 29.5 NGF TAC1
3 amyloidosis, primary localized cutaneous, 1 11.3
4 epidermolysis bullosa pruriginosa 11.3
5 amyloidosis, primary localized cutaneous, 2 11.3
6 amyloidosis, primary localized cutaneous, 3 11.3
7 dermatitis 10.5
8 lymphoma 10.4
9 hepatitis 10.3
10 bullous pemphigoid 10.3
11 neuropathy 10.3
12 lymphoma, hodgkin, classic 10.2
13 vitiligo-associated multiple autoimmune disease susceptibility 1 10.2
14 contact dermatitis 10.2
15 allergic contact dermatitis 10.2
16 keratoacanthoma 10.2
17 neurodermatitis 10.2
18 uremia 10.2
19 scabies 10.2
20 herpes zoster 10.2
21 lichen planus 10.2
22 depression 10.2
23 vasomotor rhinitis 10.1 RNASE3 TAC1
24 hashimoto thyroiditis 10.1
25 ige responsiveness, atopic 10.1
26 systemic lupus erythematosus 10.1
27 celiac disease 1 10.1
28 dermatitis herpetiformis, familial 10.1
29 becker nevus syndrome 10.1
30 lymphoma, non-hodgkin, familial 10.1
31 psoriasis 7 10.1
32 anxiety 10.1
33 psoriasis 11 10.1
34 alpha-1-antitrypsin deficiency 10.1
35 gastric cancer 10.1
36 psoriasis 13 10.1
37 burns 10.1
38 chronic kidney failure 10.1
39 hemangioma 10.1
40 colitis 10.1
41 collagenous colitis 10.1
42 igg4-related disease 10.1
43 filariasis 10.1
44 skin epithelioid hemangioma 10.1
45 squamous cell carcinoma 10.1
46 hepatitis c 10.1
47 neuroma 10.1
48 transitional cell carcinoma 10.1
49 porokeratosis 10.1
50 bladder urothelial carcinoma 10.1

Graphical network of the top 20 diseases related to Prurigo Nodularis:



Diseases related to Prurigo Nodularis
Sources

Symptoms & Phenotypes for Prurigo Nodularis

About this section
Sources

Drugs & Therapeutics for Prurigo Nodularis

About this section

Drugs for Prurigo Nodularis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 63)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
2 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
3 Central Nervous System Depressants Phase 4,Phase 2,Phase 3
4 Anesthetics Phase 4
5 Anti-Arrhythmia Agents Phase 4
6 Anesthetics, Local Phase 4
7 Sodium Channel Blockers Phase 4
8 Diuretics, Potassium Sparing Phase 4
9
Nalbuphine Approved Phase 2, Phase 3,Phase 3 20594-83-6 5311304 5360630
10 Serlopitant Investigational Phase 3,Phase 2 860642-69-9
11 Neurotransmitter Agents Phase 3,Phase 2,Not Applicable
12 Antipruritics Phase 2, Phase 3,Phase 3,Phase 1
13 Analgesics Phase 2, Phase 3,Phase 3,Phase 1
14 Analgesics, Opioid Phase 2, Phase 3,Phase 3
15 Narcotics Phase 2, Phase 3,Phase 3
16 Neurokinin-1 Receptor Antagonists Phase 3,Phase 2
17
Substance P Phase 3,Phase 2 33507-63-0 44359816
18 neurokinin A Phase 3,Phase 2
19
Apremilast Approved, Investigational Phase 2,Phase 1 608141-41-9 11561674
20
Pimecrolimus Approved, Investigational Phase 2 137071-32-0 17753757 6447131
21
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754
22
Tacrolimus Approved, Investigational Phase 2 104987-11-3 6473866 445643 439492
23
Hydrocortisone acetate Approved, Vet_approved Phase 2 50-03-3
24 Immunologic Factors Phase 2,Phase 1
25 Immunosuppressive Agents Phase 2,Phase 1
26 Anti-Inflammatory Agents Phase 2,Phase 1
27 Angiogenesis Modulating Agents Phase 2,Phase 1
28 Angiogenesis Inhibitors Phase 2,Phase 1
29 Anti-Infective Agents Phase 2,Phase 1,Not Applicable
30 Antirheumatic Agents Phase 2,Phase 1
31 Anti-Bacterial Agents Phase 2,Phase 1,Not Applicable
32 Anti-Inflammatory Agents, Non-Steroidal Phase 2,Phase 1
33 Analgesics, Non-Narcotic Phase 2,Phase 1
34 Dermatologic Agents Phase 2,Phase 1
35 Calcineurin Inhibitors Phase 2
36 Hydrocortisone 17-butyrate 21-propionate Phase 2
37 Hydrocortisone hemisuccinate Phase 2
38 Hydrocortisone-17-butyrate Phase 2
39 Pharmaceutical Solutions Phase 2
40
Citalopram Approved Not Applicable 59729-33-8 2771
41
Dapsone Approved, Investigational Not Applicable 80-08-0 2955
42
leucovorin Approved Not Applicable 58-05-9 143 6006
43
Folic Acid Approved, Nutraceutical, Vet_approved Not Applicable 59-30-3 6037
44 Psychotropic Drugs Not Applicable
45 Parasympatholytics Not Applicable
46 Autonomic Agents Not Applicable
47 Serotonin Agents Not Applicable
48 Antidepressive Agents, Second-Generation Not Applicable
49 Muscarinic Antagonists Not Applicable
50 Cholinergic Antagonists Not Applicable

Interventional clinical trials:

(show all 15)
# Name Status NCT ID Phase Drugs
1 Pain Outcomes Following Intralesional Corticosteroid Injections Recruiting NCT03630198 Phase 4 Corticosteroid with lidocaine;Corticosteroid with normal saline
2 Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis Completed NCT02174419 Phase 2, Phase 3 nalbuphine HCl ER tablets 90 mg BID;nalbuphine HCl ER tablets 180 mg BID;Placebo tablets BID
3 Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis Completed NCT02174432 Phase 2, Phase 3 nalbuphine HCl ER 90 mg BID;nalbuphine HCl ER 120 mg BID;nalbuphine HCl ER 180 mg BID
4 Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis Recruiting NCT03677401 Phase 3 5mg Serlopitant Tablets;Placebo Tablets
5 Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis Recruiting NCT03546816 Phase 3 5mg Serlopitant Tablets;Placebo Tablets
6 PRISM Study-Pruritus Relief Through Itch Scratch Modulation Recruiting NCT03497975 Phase 2, Phase 3 Nalbuphine ER Tablets
7 Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch) Recruiting NCT03540160 Phase 3 5 mg Serlopitant Tablets
8 A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN) Completed NCT02196324 Phase 2 serlopitant;Placebo
9 Safety and Efficacy of CC-10004 for Prurigo Nodularis Completed NCT00869089 Phase 2 CC-10004
10 Evaluation of the Antipruritic Effect of Elidel (Pimecrolimus) in Non-atopic Pruritic Disease Completed NCT00507832 Phase 2 Pimecrolimus;Hydrocortisone;Pimecrolimus
11 Safety and Efficacy of Nemolizumab in PN Completed NCT03181503 Phase 2 CD14152 Dose A;CD14152 placebo
12 A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Prurigo Nodularis Recruiting NCT03816891 Phase 2 KPL-716;Placebo
13 Apremilast as Anti-pruritic Treatment in Patients With Prurigo Nodularis Recruiting NCT03576287 Phase 1, Phase 2 Apremilast Oral Product
14 Effectiveness of the Selective Serotonin Reuptake Inhibitor,Citalopram (Cipralex), in Prurigo Nodularis Unknown status NCT00532519 Not Applicable citalopram (cipralex)
15 Dapsone Prurigo Study Not yet recruiting NCT01870050 Not Applicable Dapsone gel - verum

Search NIH Clinical Center for Prurigo Nodularis

Sources

Genetic Tests for Prurigo Nodularis

About this section
Sources

Anatomical Context for Prurigo Nodularis

About this section

MalaCards organs/tissues related to Prurigo Nodularis:

42
Skin, Kidney, Thyroid, Tonsil, Testes, Endothelial, T Cells
Sources

Publications for Prurigo Nodularis

About this section

Articles related to Prurigo Nodularis:

(show top 50) (show all 241)
# Title Authors Year
1
Dermatoscopic Features of Prurigo Nodularis. ( 30984602 )
2019
2
Association between prurigo nodularis and malignancy in middle-aged adults. ( 30954580 )
2019
3
Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial. ( 30894279 )
2019
4
Dramatic improvement of generalized prurigo nodularis with dupilumab. ( 30893496 )
2019
5
Treatment-resistant prurigo nodularis: challenges and solutions. ( 30881076 )
2019
6
Corticosteroid-resistant prurigo nodularis: a rare syringotropic variant associated with hypohidrosis. ( 30827950 )
2019
7
Aberrant Expression of Histamine-independent Pruritogenic Mediators in Keratinocytes may be Involved in the Pathogenesis of Prurigo Nodularis. ( 30809683 )
2019
8
Prurigo nodularis and pembrolizumab: A therapeutic challenge. ( 30735833 )
2019
9
Dupilumab Treatment for Generalized Prurigo Nodularis. ( 30427994 )
2019
10
A systematic review of evidence-based treatments for prurigo nodularis. ( 30261199 )
2019
11
Aprepitant in Anti-histamine-refractory Chronic Nodular Prurigo: A Multicentre, Randomized, Double-blind, Placebo-controlled, Cross-over, Phase-II trial (APREPRU). ( 30653242 )
2019
12
Generalized eruptive keratoacanthoma with vitiligo followed by the development of prurigo nodularis: A case report and published work review. ( 29058335 )
2018
13
Scabies presenting as cutaneous nodules or malar erythema: reports of patients with scabies surrepticius masquerading as prurigo nodularis or systemic lupus erythematosus. ( 30677831 )
2018
14
Reduced Itch Associated With Dupilumab Treatment In 4 Patients With Prurigo Nodularis. ( 30427989 )
2018
15
The Prevalence of Psychiatric Comorbidity in Patients with Prurigo Nodularis. ( 30258799 )
2018
16
Prurigo Nodularis after Radiotherapy: An Isoradiotopic Response? ( 30245894 )
2018
17
Xerosis cutis and associated co-factors in women with prurigo nodularis. ( 30156616 )
2018
18
Comprehending prurigo nodularis: Ay, there's the rub. ( 30092325 )
2018
19
Prurigo Nodularis and Its Management. ( 29929592 )
2018
20
Prurigo nodularis: a physician survey to evaluate current perceptions of its classification, clinical experience and unmet need. ( 29869425 )
2018
21
Ethnic differences and comorbidities of 909 prurigo nodularis patients. ( 29733939 )
2018
22
Thalidomide for the treatment of chronic refractory prurigo nodularis. ( 29634881 )
2018
23
The use of biodegradable microneedle patches to increase penetration of topical steroid for prurigo nodularis. ( 29521638 )
2018
24
Rapid improvement of prurigo nodularis with cyclosporine treatment. ( 29438756 )
2018
25
Allergic contact dermatitis caused by chloramphenicol with prurigo nodularis-like spreading. ( 30485440 )
2018
26
Bullous pemphigoid developed in a patient with prurigo nodularis. ( 27511319 )
2017
27
Acquired elastotic hemangioma-like changes and eccrine sweat duct squamous metaplasia in lichen simplex chronicus/prurigo nodularis-like lesions of the knee and elbow. ( 28374436 )
2017
28
There is no functional small-fibre neuropathy in prurigo nodularis despite neuroanatomical alterations. ( 28370394 )
2017
29
Acquired Reactive Perforating Dermatosis is a Variant of Prurigo Nodularis. ( 27349279 )
2017
30
Anxiety, depression and suicide in patients with prurigo nodularis. ( 27505149 )
2017
31
Use of Isoquercetin in the Treatment of Prurigo Nodularis. ( 29141065 )
2017
32
Treatment of prurigo nodularis with lenalidomide. ( 27891738 )
2017
33
Hypertrophic lichen planus versus prurigo nodularis: a dermoscopic perspective. ( 27222766 )
2016
34
Systemic methotrexate for prurigo nodularis and keratoacanthomas in actinically damaged skin. ( 27486591 )
2016
35
Prurigo Nodularis Management. ( 27578077 )
2016
36
Phototherapy for the treatment of prurigo nodularis: a review. ( 27617458 )
2016
37
A Review of the Efficacy of Thalidomide and Lenalidomide in the Treatment of Refractory Prurigo Nodularis. ( 27289372 )
2016
38
Aspirin and loxoprofen relieve refractory pruritus in patients with prurigo nodularis. ( 26970197 )
2016
39
Treatment of prurigo nodularis with dexamethasone-cyclophosphamide pulse therapy. ( 26924412 )
2016
40
The pathogenesis of Prurigo nodularis--'Super-Itch' in exploration. ( 26416433 )
2016
41
Intraepidermal Nerve Fibre Density is Decreased in Lesional and Inter-lesional Prurigo Nodularis and Reconstitutes on Healing of Lesions. ( 26338533 )
2016
42
Prurigo nodularis after acupuncture. ( 27051775 )
2015
43
Biopsychosocial Factors Associated with Prurigo Nodularis in Endogenous Eczema. ( 26538749 )
2015
44
Serotonin and interleukin-6: Association with pruritus severity, sleep quality and depression severity in Prurigo Nodularis. ( 26277226 )
2015
45
Prurigo nodularis: Picking the right treatment. ( 25973448 )
2015
46
Dermoscopy of prurigo nodularis. ( 25808786 )
2015
47
Oral tacrolimus treatment of pruritus in prurigo nodularis. ( 25804254 )
2015
48
Successful use of a modified Goeckerman regimen in the treatment of generalized prurigo nodularis. ( 25497953 )
2015
49
Prurigo nodularis as index symptom of (non-Hodgkin) lymphoma: ultrasound as a helpful diagnostic tool in dermatological disorders of unknown origin. ( 24697249 )
2015
50
Nodular Prurigo Associated with Mycosis Fungoides - Case Report. ( 26476905 )
2015
Sources

Variations for Prurigo Nodularis

About this section
Sources

Expression for Prurigo Nodularis

About this section
Search GEO for disease gene expression data for Prurigo Nodularis.
Sources

Pathways for Prurigo Nodularis

About this section

Pathways related to Prurigo Nodularis according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Phospholipase-C Pathway 65
Show member pathways
 12.55 NGF NGFR SEMA3A
2
p70S6K Signaling 65
Show member pathways
 12.52 NGF NGFR SEMA3A
3
NF-KappaB Family Pathway 65
Show member pathways
 12.12 NGF NGFR SEMA3A
4
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
11.74 NGF TAC1
5
NGF Pathway 65
Show member pathways
 11.69 NGF NGFR
6
Brain-Derived Neurotrophic Factor (BDNF) signaling pathway 1
11.65 NGF NGFR
7
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 11.54 NGF NGFR SEMA3A
8
Immune response IFN gamma signaling pathway 23
Show member pathways
 11.45 NGF NGFR SEMA3A
9
Apoptosis and survival Anti-apoptotic TNFs/NF-kB/Bcl-2 pathway 23
Show member pathways
 11.3 NGF NGFR
10
p75(NTR)-mediated signaling 1
Show member pathways
 11.22 NGF NGFR
11
Neurotrophic factor-mediated Trk receptor signaling 1
Show member pathways
 11.15 NGF NGFR
12
Guidance Cues and Growth Cone Motility 65
10.87 NGF NGFR SEMA3A
13
14-3-3 and Regulation of BAD Activity 65
10.46 NGF NGFR
Sources

GO Terms for Prurigo Nodularis

About this section

Cellular components related to Prurigo Nodularis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.46 NGF RNASE3 SEMA3A TAC1
2 axon GO:0030424 9.13 NGF SEMA3A TAC1
3 extracellular region GO:0005576 9.02 NGF NGFR RNASE3 SEMA3A TAC1

Biological processes related to Prurigo Nodularis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.4 NGF NGFR
2 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.37 NGF NGFR
3 positive regulation of axonogenesis GO:0050772 9.26 NGF NGFR
4 neurotrophin TRK receptor signaling pathway GO:0048011 9.16 NGF NGFR
5 negative regulation of neuron projection development GO:0010977 9.02 SEMA3A
6 nerve development GO:0021675 8.96 NGF SEMA3A
7 regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043281 8.62 NGF NGFR
Sources

Sources for Prurigo Nodularis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....